Different Therapeutic Regimens for Diabetic Patients with Sulfonylureas Secondary Failure:Cost-Effectiveness Analyses and Evaluation of Life Quality / 中国药房
China Pharmacy
; (12)1991.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-528929
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE:
To compare the cost-effectiveness and quality of survival among different therapeutic regimens for diabetic patients with sulfonylureas secondary failure(SSF).METHODS:
The cost-effectiveness and the effects on patients life quality of four therapeutic schemes(group A mixed-human insulin;group Brepaglinide and metformin;group Crepaglinide and acarbose;group Dglipizide,metfonmin and novolin N) were compared using cost-effectiveness analysis in pharmacoeconomics and DSQOL(diabetic patients’ score on quality of life).RESULTS:
Group A showed the best clinical efficiency,with cost-effectiveness ratio significantly lower,physiological and psychological dimension scores significantly higher and social dimension score significantly lower than in all the other 3 groups,and all were of significant differences,but no significant differences were noted in therapeutic dimension score as compared with the other 3 groups.CONCLUSION:
Insulin is optimal among four schemes in the treatment of diabetic patients with sulfonylureas secondary failure in the cost-effectiveness analysis, and it has the best efficacy in the improvement of patients’ physiology and psychology.
Texto completo:
Disponível
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
Problema de saúde:
Objetivo 4: Financiamento para a saúde
Base de dados:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Avaliação econômica em saúde
Aspecto:
Preferência do paciente
Idioma:
Chinês
Revista:
China Pharmacy
Ano de publicação:
1991
Tipo de documento:
Artigo